Scientific Factors and Current Issues in Biosimilar Studies
- 31 October 2014
- journal article
- Published by Taylor & Francis Ltd in Journal of Biopharmaceutical Statistics
- Vol. 24 (6), 1138-1153
- https://doi.org/10.1080/10543406.2014.948961
Abstract
Biological drugs are much more complicated than chemically synthesized, small-molecule drugs; for instance, their size is much larger, their structure is more complicated, they can be sensitive to environmental conditions such as temperature or pressure, and they may expose patients to immunogen reactions. Consequently, the assessment of biosimilarity calls for greater circumspection than the evaluation of bioequivalence. The present communication discusses scientific factors and some current issues related to biosimilarity and the interchangeability of drug products. The scientific factors include questions involving endpoint selection, the one-size-fits-all criterion, and the need for a more flexible approach, e.g., evaluation of the degree of similarity (i.e., responding to the question of "how similar is similar?"; a review of study designs that are useful for the assessment of biosimilarity and drug interchangeability; and tests for the comparability of critical quality attributes at various stages of the manufacturing process). Current issues include the choice of reference standards and the relevant study designs; criteria for biosimilarity, as well as for interchangeability and for comparability; the determination of the noninferiority margin; and the concepts of the stepwise approach to biosimilarity studies and of their assessment by the totality of the evidence. The calculation of sample sizes is discussed for crossover (including some higher-order schemes) and parallel designs.Keywords
This publication has 12 references indexed in Scilit:
- Assessing biosimilarity and interchangeability of biosimilar productsStatistics in Medicine, 2013
- Statistical assessment of biosimilarity based on relative distance between follow-on biologicsStatistics in Medicine, 2012
- Impact of variability on the choice of biosimilarity limits in assessing follow‐on biologicsStatistics in Medicine, 2012
- Comments on the FDA draft guidance on biosimilar productsStatistics in Medicine, 2012
- Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologicsBiosimilars, 2011
- Bioequivalence Approaches for Highly Variable Drugs and Drug ProductsPharmaceutical Research, 2007
- Assessing individual bioequivalence using the structural equation modelStatistics in Medicine, 2003
- Statistical evaluation of individual bioequivalenceCommunications in Statistics - Theory and Methods, 1998
- Power of the two one-sided tests procedure in bioequivalenceJournal of Pharmacokinetics and Biopharmaceutics, 1990
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987